EC Number   |
Application |
Reference  |
|---|
   3.4.22.32 | medicine |
the complex between stem bromelain and polyclonal Fab* monomer can serve as a model with potential in vivo and industrial application especially in homogenous reaction phases and development of subunit vaccines owing to preponderance of hydrophobic interaction and better diffusion potential of Fab' than of intact IgG |
664145 |
| 3.4.22.32 | medicine |
oral bromelain may potentially modify inflammation within the gastrointestinal tract via local proteolytic activity within the colonic microenvironment |
665207 |
| 3.4.22.32 | medicine |
bromelain possesses anti-inflammatory activity and reduces blood viscosity, prevents the aggregation of blood platelets, and improves ischemia-reperfusion injury, I/R, in a skeletal muscle model in adult Sprague-Dawley rats. The enzyme increases phosphorylation of Akt in rat heart both in the cytosolic and the nuclear fraction following I/R |
677476 |
| 3.4.22.32 | medicine |
stem bromelain triggers an Akt-dependent survival pathway in the heart, revealing a mechanism of cardioprotective action and a potential therapeutic target against ischemia/perfusion injury |
677476 |
| 3.4.22.32 | medicine |
bromelain has antitumoral activity |
682476 |
| 3.4.22.32 | medicine |
bromelain shows antitumorigenic potential by inducing apoptosis-related proteins along with inhibition of nuclear factor-kappa B driven cyclooxygenase-2 expression by blocking the mitogen-activated protein kinase and Akt/protein kinase B signaling in 7,12-dimethylbenz(a)anthracene-12-O-tetradecanoylphorbol-13-acetate-induced mouse skin tumors |
682906 |
| 3.4.22.32 | medicine |
bromelain from pineapple stem shows therapeutic benefits in a variety of inflammatory diseases, including murine inflammatory bowel disease, mechanism, overview. Bromelain primary long-term effect is abrogation of firm adhesion of leukocytes to blood vessels at the site of inflammation. These changes in adhesion are correlated with rapid re-expression of the bromelain-sensitive CD62L/L-selectin molecules that mediate rolling following in vivo bromelain treatment and minimal re-expression of CD128 |
697421 |
| 3.4.22.32 | medicine |
effects of orally administered bromelain in an ovalbumin-induced murine model of acute allergic airway disease in female C57BL/6J mice, bromelain causes decreased methacholine sensitivity, reduction in bronchoalveolar lavage eosinophils and interleukin-13 concentrations, as well as of CD19+ B cells and CD8+ T cells, as compared with controls, overview. Bromelain modulates lung lymphocytes during acute asthma |
697783 |
| 3.4.22.32 | medicine |
bromelain has anti-cancer activity, as well as antithrombotic, fibrinolytic, antiedematous, and burn debridement properties |
707968 |
| 3.4.22.32 | medicine |
the nonnative form of SBM shows only a fraction of the native protein's enzymatic activity but is more effective at inhibiting cell growth and displays better antitumorigenic properties than native SBM |
708752 |
